A detailed history of Presidio Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Presidio Capital Management, LLC holds 1,829 shares of ABBV stock, worth $321,135. This represents 0.23% of its overall portfolio holdings.

Number of Shares
1,829
Previous 1,974 7.35%
Holding current value
$321,135
Previous $338,000 6.8%
% of portfolio
0.23%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$163.84 - $199.33 $23,756 - $28,902
-145 Reduced 7.35%
1,829 $361,000
Q2 2024

Jul 26, 2024

SELL
$154.79 - $180.76 $28,481 - $33,259
-184 Reduced 8.53%
1,974 $338,000
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $66,964 - $76,299
419 Added 24.09%
2,158 $392,000
Q4 2023

Jan 12, 2024

SELL
$137.6 - $154.97 $90,953 - $102,435
-661 Reduced 27.54%
1,739 $269,000
Q3 2023

Oct 25, 2023

SELL
$133.59 - $154.65 $23,645 - $27,373
-177 Reduced 6.87%
2,400 $357,000
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $8,613 - $10,718
-65 Reduced 2.46%
2,577 $347,000
Q1 2023

May 03, 2023

SELL
$144.61 - $166.54 $16,485 - $18,985
-114 Reduced 4.14%
2,642 $421,000
Q4 2022

Feb 07, 2023

SELL
$138.31 - $165.87 $27,385 - $32,842
-198 Reduced 6.7%
2,756 $445,000
Q3 2022

Nov 03, 2022

SELL
$134.21 - $153.93 $90,054 - $103,287
-671 Reduced 18.51%
2,954 $396,000
Q2 2022

Jul 27, 2022

BUY
$137.62 - $174.96 $14,450 - $18,370
105 Added 2.98%
3,625 $555,000
Q1 2022

Jun 08, 2022

SELL
$131.98 - $163.75 $4,883 - $6,058
-37 Reduced 1.04%
3,520 $571,000
Q4 2021

Jun 08, 2022

BUY
$107.43 - $135.93 $382,128 - $483,503
3,557 New
3,557 $482,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Presidio Capital Management, LLC Portfolio

Follow Presidio Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Presidio Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Presidio Capital Management, LLC with notifications on news.